Source - RNS
RNS Number : 3140R
IMI PLC
13 June 2018
 

13 June 2018

IMI PLC
(the "Company")

Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Persons Closely Associated with them

This notification relates to transactions notified in accordance with the Market Abuse Regulation, further details below:

1.

Details of the person discharging managerial responsibilities/ person closely associated

a)

Name

1. Mark Selway

2. Daniel Shook

3. Roy Twite

4. Paul Roberts

5. Massimo Grassi

2.

Reason for the notification

a)

Position/status

1. Chief Executive Officer

2. Chief Financial Officer

3. Divisional Managing Director

4. Business Development Director

5. Divisional Managing Director

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IMI plc

b)

LEI

2138002W9Q21PF751R30

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

  Identification code

Ordinary share

 
GB00BGLP8L22

b)

Nature of the transaction

Shares purchased pursuant to participation in the IMI Employee Share Ownership Plan

 

 c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.   £12.06

2.   £12.06

3.   £12.06

4.   £12.06  

5.   £12.06

10

10

11

10

12

d)

Aggregated information

·      Aggregated volume

·      Price

N/A Single transaction

e)

Date of the transaction

12 June 2018

f)

Place of the transaction

London Stock Exchange Main Market (XLON)






 

For further information, please contact:

John O'Shea
Group Legal Director and Company Secretary
Telephone: 0121 717 3700


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHSFIFLDFASEEM